04.02.2025



DESK NOTE

Centrus Energy Corp. (LEU US) – Hello, HALEU! A strategic buy as Centrus nuclear transformation unlocks major upside!

Conclusive Summary: LEU stock presents a high-risk, high-reward investment opportunity within the evolving nuclear energy landscape. **Centrus is the only publicly traded company focused on nuclear fuel enrichment** and **the sole U.S. corporation licensed to produce HALEU**— the next-generation nuclear fuel. Notably, 9 out of 10 reactors selected by the U.S. Department of Energy's Advanced Reactor Demonstration Program are designed to operate on HALEU. **Centrus is transitioning from a distributor of LEU to a producer of advanced nuclear fuels**, **a shift expected to drive substantial growth and long-term value creation**. This transformation aligns with the global "nuclear renaissance," a favorable regulatory environment, and rising demand for low-carbon energy solutions, as outlined in our recent desk note on uranium. By 2035, Centrus's annual market opportunity is projected to reach \$2.4B. We recommend LEU as a medium- to long-term buy, with a 12-month upside of 51%.

Competitive Position: Centrus has made **significant investments in next-generation enrichment technologies**, enhancing efficiency, reducing costs, and strengthening its position in the global market. **Active engagement with U.S. and allied regulators** remains a core strategic priority. The company secures recurring revenue through longterm fuel service contracts with utility companies. Additionally, Centrus has signed a **Memorandum of Understanding for a long-term partnership with Oklo**, a key developer of advanced nuclear reactors, where Sam Altman serves as Chairman and the newly appointed U.S. Secretary of Energy was a board member until January. The company has also demonstrated its ability to **successfully navigate the complexities of delivering LEU from Russia's TENEX** to global customers despite the constraints of a bilateral sanctions regime.

Valuation: A 12-month target price of \$124 is based on a combination of DCF and multiple analysis (with \$84 attributed to LEU's current operations and \$46 - to the HALEU opportunity within DCF analysis). Given Centrus's ongoing business transformation, historical multiples have limited relevance.


Ticker: LEU US

Previous day close price: \$81.87 Price range (52w): \$ 33.51 - \$118.36 Target price (12m): \$124 (+51% upside)

Recommendation: **Buy @82**

Description: Centrus is a U.S.-based supplier of nuclear fuel and services, specializing in uranium enrichment. Market cap is \$1.24B. It has two primary segments: 1) Low-Enriched Uranium (LEU) - 84% of revenue; 2) Technical Solutions (16%). The LEU – trading/distribution - segment provides enriched uranium used as fuel in commercial nuclear power reactors, including sales of Separative Work Units (SWU) and uranium hexafluoride. The Technical Solutions - production - segment focuses on advanced nuclear fuel development, including High-Assay Low-Enriched Uranium (HALEU) production, which is crucial for nextgeneration reactors. HALEU has 5-20% of its content as U-235 compared to 3-5% in LEU. Centrus is the only U.S. company licensed to produce HALEU and has an enrichment facility in Piketon, Ohio. Leading customers include Fortune 500 utilities. Major competitors in enrichment: TENEX (Rosatom, Russia), CNEIC (China), Urenco (UK, Netherlands, Germany consortium), Orano (France), Global Laser Enrichment (GLE, U.S./Australia with 49% belonging to CCJ US). U.S. federal programs have already allocated ~\$3.3B toward HALEU and LEU production, with further investments expected.

Valentin Zhurba, <u>vz@dprginvestment.com</u> Tel: +357 223 22030





Private and Confidential. For Designated Party only.

Disclaimer: This document is issued by DPRG IM LTD (HE433850), a Cyprus investment Firm authorized and regulated by the Cyprus Securities and Exchange Commission (CySEC) to offer certain investment and ancillary services and activities under the provisions of the investment Services, the Exercise of Investment Activities, the Operation of Regulated Markets, and Other Related Matters I aw of 2017, Law 87(I)/2017, as subsequently amended or replaced from time to time (the "Law"), with CIF license number (license number to be added upon authorization. The information contained herein is for informational purposes only and does not constitute an offer to buy or sell any financial instrument, nor should the considered as personalized investment advice. Investments involve significant risks, including the potential loss of the initial investment. Past performance is not indicative of future results. DPRG IM LTD and its affiliates may hold positions in the financial instruments mentioned herein, which may create potential conflicts of interest. The company adheres to strict compliance policies to manage such conflicts and ensure transparency. For further details, please contact <u>compliance@drpginvestment.com</u> or +357 22322030.